Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

    Home > Events > Veristat to exhibit at outsourcing in clinical trials southeast 2017

    1 min read

    Veristat to Exhibit at Outsourcing in Clinical Trials Southeast 2017

    LinkedIn Image_OCT Southeast_Post 1.pngVeristat is excited to join clinical research professionals to discuss the key challenges faced by small to mid-sized biotech and pharma companies at the Outsourcing in Clinical Trials Southeast 2017 event.  Speaking topics will span both clinical outsourcing and clinical operations challenges such as vendor sourcing, contract development, regulatory compliance, patient enrollment, budget adherence and more.

     

    About The Conference

    The conference will cover many exciting topics including:

    •  Maximizing your Phase I and Phase II data to ensure a smooth Phase III
    • Outsourcing in Oncology – Overcoming Common Pitfalls and Celebrating Success

    • Considering adaptive design when outsourcing studies to vendors to improve decision making throughout phases

    • Considering patient and site perspectives when designing a study to increase enrollment and retention rates

     

    Visit Our Booth #8

    Meet up with Veristat while you are at OCT Southeast!    Don’t forget to stop by our booth #8 to meet with our experts to talk about the challenges you are facing with your clinical trial design, execution and regulatory submission projects.    

     

    Schedule A Meeting

    Fill out the form on the right to schedule a specific time to meet with Jessica Young or Derek Luther at the conference.

     

    Share This Event:

       

    11 min read

    Monthly FDA Guidance and Regulatory News Review - September 2026

    This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...

    8 min read

    Monthly FDA Guidance and Regulatory News Review - August 2026

    This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...